

ABSTRACT

The present invention provides an oral formulation of arsenic trioxide (As₂O₃) for the treatment of a variety of hematological malignancies, including acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). The present invention also 5 provides methods for making the oral arsenic trioxide formulation. Methods of using the oral arsenic trioxide formulation are also described.